Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
McKinsey
Queensland Health
McKesson
Merck
Baxter
Chinese Patent Office
Chubb

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,952,375

« Back to Dashboard

Summary for Patent: 5,952,375
Title: Compounds and methods for synthesis and therapy
Abstract:Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.
Inventor(s): Bischofberger; Norbert W. (San Carlos, CA), Kim; Choung U. (San Carlos, CA), Lew; Willard (San Mateo, CA), Liu; Hongtao (Foster City, CA), Williams; Matthew A. (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:08/606,624
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,952,375
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 5,952,375

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 5,952,375

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 191711 ➤ Try a Free Trial
Austria 305453 ➤ Try a Free Trial
Australia 5357196 ➤ Try a Free Trial
Australia 720933 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Teva
Healthtrust
Argus Health
Medtronic
Accenture
Johnson and Johnson
Cerilliant
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.